CurvaFix, Inc. has positioned itself as an innovative player in the medical devices industry, with a strong focus on improving fracture repair in curved bones. Founded in 2013 and headquartered in the United States, CurvaFix has garnered attention for its unique offering, the CurvaFix® IM Implant, touted as the only curved intramedullary implant designed to follow and fill the patient’s individual pelvic anatomy. With a specific emphasis on Fragility Fractures of the Pelvis (FFP) and high-impact pelvic fractures, the company holds potential for transformative impact within the healthcare sector.
The recent $39.00M Series C investment in the company, which took place on 14 July 2023, signals a significant show of confidence from prominent investors such as Sectoral Asset Management and MVM Life Science Partners. This injection of capital not only underscores the potential of CurvaFix's offerings but also provides the necessary resources for further research, development, and market expansion. As CurvaFix continues to advance its proprietary implantable products, the latest investment round sets the stage for the company to solidify its position as a key player in enhancing fracture repair and addressing the specific needs of curved bone interventions.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series C | $39.00M | 2 | MVM Life Science Partners | 14 Jul 2023 |
Convertible Note | $3.00M | 1 | SWAN Venture Fund | 06 Jun 2023 |
Convertible Note | $5.00M | 1 | SWAN Venture Fund | 03 Jun 2022 |
Series B | $10.70M | 3 | Delta Dental of Washington | 21 Jul 2020 |
Convertible Note | Unknown | 2 | SWAN Venture Fund | 01 May 2019 |
No recent news or press coverage available for CurvaFix, Inc..